Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
21:32
Australian police are investigating the Australian connections of a Flydubai co-pilot accused of attacking his captain during the flight
21:08
DNSC warns TPARK users: Fake messages demand urgent payment of alleged parking fines
20:44
The Mecca Defense Pact Committee will meet in Riyadh on Monday to discuss the crisis in Yemen and regional developments
20:33
The Romanian College of Physicians calls for measures to prevent fires following the fire at the Brașov Pneumology Hospital
20:08
Călin Georgescu’s supporters sang “Eternal Memory” for Cristian Tudor Popescu during the protest at the Central Detention Center: “It seems I have died”
See more news